Sarcopenia, Asthma, Dyspnea, Dyspnea; Asthmatic, Cytokines, Adipokines, Myokine, Muscle Disorder
Conditions
Keywords
Asthma, Sarcopenia, Dyspnea
Brief summary
Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses. The impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea . The morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction. The investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.
Interventions
DIAGNOSTIC_TESTmuscle evaluation
The investigators will evaluate the muscle mass and muscle strenght for all patients included
BIOLOGICALDosage
Evaluation of the cinetic of biomarkers during exercise
DIAGNOSTIC_TESTCardiopulmonary exercise test
CPET
COMBINATION_PRODUCTQuestionnaire and Physical Exam
Evaluating dyspnea, anxiety, sleep, physical activity, quality of life
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Patient affiliated to a social security scheme. * Patient capable of giving free, informed, written and signed consent. * Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment * ACT asthma control score \< 20 * Patient judged by the investigator to be able to to perform a maximal exercise test.
Exclusion criteria
* Patient under guardianship/trusteeship/supervision of justice * Pregnant or breast-feeding women * Unstable heart disease * Patients who have been smoking or have stopped smoking for less than 5 years,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation in the intensity of dyspnea during exercise mesured with Borg scale (0-10) according to the presence of sarcopenia | From baseline (at rest) to the end of the exercise | Recording of Borg's dyspnea score during exercise on a scale of 0 (no dyspnea) to 10 (major dyspnea) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Variation in exercise-induced release of biomarkers according to the presence of sarcopenia | at rest = baseline / right after the end of exercice / 45 minutes after the end of exercice | Variation of cytokine as IL-1, IL-6, IL-8, IL-10 and TNF-alpha plasma concentrations (pg/mL) ; adipokines ; myokines |
| Difference in muscle mass (kg) on impedancemetry according to the presence of sarcopenia | Baseline | — |
| Difference on maximum aerobic capacity (VO2 max in L/mn) , according to the presence of sarcopenia | immediately after the exercise test | Difference on physical activity |
| Difference in fat mass (kg) on impedancemetry according to the presence of sarcopenia | At baseline | — |
Countries
France
Contacts
Primary ContactLise Laclautre
Outcome results
None listed